- Home
- CANF
as 07-26-2024 4:00pm EST
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 13.5M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 132.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $4.69 | Next Earning Date: | 08-15-2024 |
| Revenue: | $743,000 | Revenue Growth: | -12.90% |
| Revenue Growth (this year): | 356.93% | Revenue Growth (next year): | N/A |
Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) News
CANF Breaking Stock News: Dive into CANF Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
GlobeNewswire
16 days ago
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
GlobeNewswire
a month ago
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
Business Wire
a month ago
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
Business Wire
a month ago
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
Business Wire
2 months ago
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Compare CANF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.